Project Grant K01HL168214
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$168K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), is funding research to investigate the role of heme-induced complement activation in sickle cell disease (SCD) pregnancy. The $202,366 award, effective September 1, 2024 through August 31, 2025, will support a two-part study using a mouse model of SCD. The first aim will characterize the effects of SCD and heme-induced complement...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $191,792 to the University of Rochester to conduct formative implementation research on translating evidence-based interventions to improve inpatient care for patients with sickle cell disease (SCD). The key objectives are to: 1) develop an individualized care plan (ICP) prototype adapted from the emergency department setting for...
This $483,852 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop a high-throughput platform to measure the equilibrium and kinetics of hemoglobin polymerization in single red blood cells for sickle cell disease. The platform will enable the evaluation of new treatments targeting hemoglobin polymerization, such as gene therapy, gene editing, and hemoglobin affinity modulation. The grant...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $827,753.90 to Bloodworks (doing business as Puget Sound Blood Center and Program) to conduct research on oxidative stress and cysteine modification in sickle cell disease. The research aims to investigate how thiol isomerases, a class of oxidoreductase enzymes, promote vaso-occlusion - a major clinical burden in sickle cell...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $172,176 Project Grant to Albert Einstein College of Medicine to conduct a pilot study titled "Reducing Morbidity in Sickle Cell Disease-PREVENT Acute Chest Syndrome System (PACSYSTEM) Pilot Study." This 5-year grant, awarded on June 1, 2024, aims to improve health outcomes for children and youth with sickle cell disease by using implementation science methods to address barriers and enablers faced by healthcare...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), is for the "Cardiovascular Diseases Research" program (CFDA 93.837). The $156,340 award will fund a 5-year research project to develop and test a communication-enhancement intervention for healthcare providers to improve health outcomes in pediatric sickle cell disease. The research activities include conducting qualitative research to refine the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a 5-year, $637,526 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Duke University. The grant supports research to investigate how sickle cell disease (SCD) impacts neutrophil activation and function. The project aims to delineate the specific mechanisms by which sickle red blood cells (RBCs) directly induce neutrophil activation in SCD, and examine if these interactions correlate with acute...
The U.S. Centers for Disease Control and Prevention (CDC) awarded a $286,510 Cooperative Agreement under the Blood Disorder Program: Prevention, Surveillance, and Research (CFDA 93.080) to the Center for Public Health Innovation, a woman-owned non-profit organization, for the Sickle Cell Data Collection Program - 2023. This 5-year project, beginning on September 30, 2023, aims to work with state health agencies and other partners to plan, develop, implement, coordinate, and evaluate programs and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $607,535 to the University of Illinois to investigate the effects of the compound hemin on the pulmonary endothelium and its role in the development of pulmonary complications associated with sickle cell disease. The research aims to evaluate the concentration-dependent effects of hemin on pulmonary artery endothelial cells,...
This federal Project Grant award, totaling $608,126.00 and awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop and validate single-cell biomarkers for predicting clinical outcomes in sickle cell disease (SCD). The grant supports research to: Define the relationship between SCD adverse clinical outcomes and single-cell biochemical and mechanical properties to identify promising biomarkers. Define the...